Home›Trial›NCT06236750
NCT06236750NARECRUITING

Post-Marketing Surveillance of Dehydrated Human Amnion/Chorion Membrane (DHACM) in Non-Ischemic Chronic Wounds

Study Summary

The purpose of this survey is to observe the efficacy and safety of EPIFIX® dehydrated human amnion/chorion membrane (DHACM) for the treatment of intractable diabetic foot ulcers or venous leg ulcers.

Conditions
Diabetic Foot UlcerVenous Leg Ulcer
Interventions / Drugs
EPIFIX
View on ClinicalTrials.gov ↗
Sponsor
MDXG
MiMedx Group
Regenerative Medicine
D38/100
Study Details
Enrollment75 participants
Primary Completion—
Lead SponsorMiMedx Group, Inc.
Data Retrieved2026-04-11 04:20:58.628818+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 75 participants
Sponsor Catalyst Profile

MiMedx Group (MDXG) is the sponsoring company for this trial. BiotechSign currently grades this company D (38/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

MDXG Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.